E-resources
-
Cree, Bruce A. C.; Gourraud, Pierre-Antoine; Oksenberg, Jorge R.; Bevan, Carolyn; Crabtree-Hartman, Elizabeth; Gelfand, Jeffrey M.; Goodin, Douglas S.; Graves, Jennifer; Green, Ari J.; Mowry, Ellen; Okuda, Darin T.; Pelletier, Daniel; von Büdingen, H.-Christian; Zamvil, Scott S.; Agrawal, Alisha; Caillier, Stacy; Ciocca, Caroline; Gomez, Refujia; Kanner, Rachel; Lincoln, Robin; Lizee, Antoine; Qualley, Pamela; Santaniello, Adam; Suleiman, Leena; Bucci, Monica; Panara, Valentina; Papinutto, Nico; Stern, William A.; Zhu, Alyssa H.; Cutter, Gary R.; Baranzini, Sergio; Henry, Roland G.; Hauser, Stephen L.
Annals of neurology, October 2016, Volume: 80, Issue: 4Journal Article
Objective To characterize the accrual of long‐term disability in a cohort of actively treated multiple sclerosis (MS) patients and to assess whether clinical and magnetic resonance imaging (MRI) data used in clinical trials have long‐term prognostic value. Methods This is a prospective study of 517 actively managed MS patients enrolled at a single center. Results More than 91% of patients were retained, with data ascertained up to 10 years after the baseline visit. At this last assessment, neurologic disability as measured by the Expanded Disability Status Scale (EDSS) was stable or improved compared to baseline in 41% of patients. Subjects with no evidence of disease activity (NEDA) by clinical and MRI criteria during the first 2 years had long‐term outcomes that were no different from those of the cohort as a whole. 25‐OH vitamin D serum levels were inversely associated with short‐term MS disease activity; however, these levels had no association with long‐term disability. At a median time of 16.8 years after disease onset, 10.7% (95% confidence interval CI = 7.2–14%) of patients reached an EDSS ≥ 6, and 18.1% (95% CI = 13.5–22.5%) evolved from relapsing MS to secondary progressive MS (SPMS). Interpretation Rates of worsening and evolution to SPMS were substantially lower when compared to earlier natural history studies. Notably, the NEDA 2‐year endpoint was not a predictor of long‐term stability. Finally, the data call into question the utility of annual MRI assessments as a treat‐to‐target approach for MS care. Ann Neurol 2016;80:499–510
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.